INDIA – Gurugram-based Pathkind Labs has joined forces with Roche Diagnostics to release cardiac biomarker dubbed NTProBNP that will be used in the management of Type 2 Diabetes (T2DM).

NTProBNP is a direct predictor of adverse outcome and cardiovascular mortality, making this marker instrumental in the management of CVDs in T2D patients.

Under the agreement, Pathkind Labs will use the gold-standard biomarker for identification of the risk of heart failure and cardiovascular disease (CVD) risk factors in people living with T2DM.

With the incorporation of NTProBNP in diabetes management, Pathkind will be a leader in providing comprehensive and holistic diabetes and cardiac care,” the diagnostic services chain claimed.

In a press release, Pathkind said that it intends to incorporate NTProBNP, a simple blood test, to help detect and monitor heart failure as part of diabetes treatment and management.

The high-sensitivity test will also assist healthcare professionals and patients in making important medical decisions including decisions about treatments and interventions.

It also holds a pivotal role in the evaluation of diabetic heart failure patients’ overall status, facilitating the establishment of correct therapy management and follow-up.

Moreover, it is paramount for healthcare professionals to re-evaluate how they treat and manage a challenging patient population to curb the disease burden of diabetes in India and beyond.

Sanjeev Vashishta, Managing Director & Chief Executive Officer (CEO) Pathkind Labs stressed: “Diabetes patients must receive a prompt diagnosis of heart disease in order to manage their health to the best of their ability.”

He observed that the co-existence of diabetes mellitus and heart failure has significant clinical and economic implications in terms of clinical visits, hospital admissions, quality of life, morbidity, and mortality.

On his part, Narendra Varde, Managing Director, Roche Diagnostics India & Neighboring Markets said: “Today, modern technology and our evolving understanding of disease have given us newer options for personalising therapy, reducing unnecessary expenses, and protecting those in need.”

He underscored that it is crucial to screen people with T2DM for CVD risk in order to lower mortality and CVD events, adding that the partnership with Pathkind will be a turning point in diabetes management.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.